<?xml version="1.0" encoding="UTF-8"?>
<p>For instance, herbacetin, epigallocatechingallate, rhoifolin, pectolinarin, hesperidin, cannabinoids, and morin showed better docking poses than did nelfinavir, hydroxychloroquine sulfate, and chloroquine (
 <xref rid="B43" ref-type="bibr">43</xref>). Nevertheless, these substances have low oral bioavailability except a few of them, i.e., pectolinarin, epigallocatechingallate, myristicin, and eugenol (
 <xref rid="T1" ref-type="table">Table 1</xref>). The low oral bioavailability of these substances illustrates a real problem for drug designers. The substances may have high effectiveness in 
 <italic>in vivo</italic> and/or 
 <italic>in vitro</italic> studies; it may fail as a new drug, when considered in clinical trials, besides the oral availability of some compounds, which may decrease if combined with food (
 <xref rid="B48" ref-type="bibr">48</xref>). Therefore, the oral bioavailability of phytogenic compounds must be taken into consideration, when predicting them as candidate drugs.
</p>
